The company also reported it completed 244,000 Cologuard tests during 2016, a 134 percent increase from 2015.
The company said it expects revenues of $52 million to $53 million for the quarter, compared to analysts' average estimate of $63.1 million.
The company said it expects a 1 percent increase in 2016 revenues, but noted that the results were adversely affected by certain competitive pressures in Q4, among other problems.
The South San Francisco, California-based firm said instrument revenues fell 39 percent, driven by lower-than-average sales of its Helios mass cytometry system.
The company missed its expectations due to declining orders for its HiSeq 2500 and HiSeq 4000 instruments and one fewer order for its HiSeq X Ten system.
Revenues rose thank to an increase in the company's human health business, which offset a decline in its environmental health segment.
The release clarifies issues related to the timing of revenue recognition for transactions outside the US.
Illumina expects $572 million in first quarter revenues, due to low HiSeq 2500, 3000, and 4000 sales and weak business in Europe, and lowered its full year forecast.
The GenomeWeb Index fell 11 percent in January, behind the Dow and the Nasdaq, but well above the Nasdaq Biotech Index, which fell 21 percent.
The company attributed the growth in quarterly revenue to sales of its existing products and early interest in its new single-cell genomics system.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.